Core Points - Castellum, Inc. has been awarded a $66.2 million contract for logistics, engineering, and cyber support services for the Naval Air Warfare Center Aircraft Division, marking its first full and open prime contract win without small-business set-aside restrictions and the second-largest contract in the company's history [1][2][3] Group 1: Contract Details - The awarded contract is a five-year agreement aimed at supporting the Mission Operations & Integration Department at NAWCAD Lakehurst, which is responsible for Navy Aircraft Platform Support Equipment and Aircraft Launch Recovery Equipment [1][3] - Specialty Systems, Inc. will provide services related to logistics, engineering, and cyber work products for aircraft carriers and air-capable ships [1][3] Group 2: Company Strategy and Performance - The contract win reflects the effectiveness of Castellum's strategy to focus on full and open opportunities as it transitions to a larger business model [4] - Castellum has secured two major prime contracts in the past seven months, including a $103 million contract announced in February, indicating strong growth and competitiveness in the market [5] Group 3: Leadership and Team Recognition - The leadership at Castellum emphasizes the dedication and skills of its professionals, attributing the contract win to their hard work and commitment to providing world-class service [6] - The company expresses confidence in its team and the positive impact of these contracts on its mission capabilities and overall business growth [5][6]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (the “Fund”) (NYSE: CCIF), an externally managed closed-end fund focused on investing in primarily equity and junior debt tranches of collateralized loan obligations, has entered into a Purchase Agreement with certain institutional investors for the purchase and sale of approximately 17,500 shares of the Fund’s 7.25% Series E Convertible Preferred Shares due 2030 (the “Convertible Preferred Shares”), liquidation preference $1,000.00 per ...

Core Insights - LyondellBasell Industries reported a net loss of $890 million for Q3 2025, with diluted loss per share of $2.77, significantly down from a profit of $573 million in Q3 2024 [1][6][31] - The company recognized $1.2 billion in identified items, which included non-cash asset write-downs and costs related to various initiatives, impacting earnings by $3.78 per share [4][6] - EBITDA for Q3 2025 was $(480) million, but $835 million when excluding identified items, indicating operational challenges [4][6] Financial Performance - Sales and other operating revenues for Q3 2025 were $7.727 billion, a slight increase from $7.658 billion in Q2 2025 but down from $8.604 billion in Q3 2024 [1][4] - The net loss for the nine months ended September 30, 2025, was $598 million, compared to a profit of $1.970 billion for the same period in 2024 [1][4] - Cash from operating activities was $983 million with a cash conversion rate of 135% during Q3 2025 [4][9] Operational Highlights - The Olefins and Polyolefins Americas segment saw improved profitability due to increased olefins margins and higher sales volumes, despite a decrease in polyethylene spreads [7] - The Intermediates and Derivatives segment benefited from increased octane blend premiums and lower raw material prices, although styrene margins declined [8] - The company is executing a Cash Improvement Plan aimed at achieving $600 million in savings for 2025 and a minimum of $1.1 billion by the end of 2026 [5][10] Strategic Initiatives - LyondellBasell is focusing on operational and financial discipline, with plans to reduce capital expenditures to $1.2 billion in 2026 while supporting the construction of a chemical recycling plant in Germany [10] - The company is advancing its portfolio transformation with the sale of four European assets, which has received regulatory approvals [10] - The company plans to idle its larger cracker in Wesseling, Germany, and a propylene oxide/styrene monomer unit in Channelview, Texas, for maintenance and alignment with global demand [12][13] Market Outlook - The fourth quarter is expected to be impacted by seasonality and lower operating rates, with pressures on integrated polyolefins margins due to rising natural gas and feedstock costs in North America [11] - Weak industrial and consumer demand is anticipated to persist in Europe, although global capacity rationalizations may support a more constructive mid-term outlook for the industry [11]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (the "Company") (Nasdaq: CGBD) today announced that it intends to redeem all $85,000,000 aggregate principal amount of its outstanding 8.20% Notes due 2028 (the "2028 Notes") on December 1, 2025 (the "Redemption Date"). A notice of redemption will be mailed to all registered holders of the 2028 Notes by U.S. Bank Trust Company, National Association, as successor trustee to The Bank of New York Mellon Trust Company, N.A (the "Trustee") ...

NANO Nuclear Energy Inc. Figure 1 - NANO Nuclear Energy Inc. Founder and Chairman Jay Yu will participate in multiple speaking sessions from November 3-6 at ADIPEC 2025 in Abu Dhabi, UAE, the world’s largest energy event. ADIPEC will host more than 16,500 delegates, 1,800 speakers, and over 205,000 attendees for high-level discussions shaping the future of energy. New York, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advance ...

Group 1 - Mark Draper, an employee-elected member of the Board of Directors, will resign from his position at Scandinavian Tobacco Group A/S on 31 October 2025 [2] - Hanne Malling, the Trademark Manager, will replace Mark Draper on the Board of Directors starting 1 November 2025 for the remainder of the current term, which lasts until the annual general meeting in 2027 [2]

CALGARY, Alberta, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) today announced its third-quarter 2025 financial and operating results. The company generated approximately $2.1 billion in cash from operating activities, $2.5 billion of adjusted funds flow and $1.3 billion of free funds flow. Operating results in the quarter included record Upstream production of 832,900 barrels of oil equivalent per day (BOE/d)1 and record Downstream crude throughput of 710,700 barrels per day ...

Core Insights - Hepsiburada, a leading Turkish e-commerce platform, will release its unaudited financial results for Q3 2025 on November 5, 2025, before the U.S. market opens [1] Company Overview - Hepsiburada operates as a hybrid e-commerce platform in Türkiye, combining first-party direct sales and a third-party marketplace with around 100,000 merchants [2] - The platform aims to lead the digitalization of commerce, providing a wide range of services including last-mile delivery, fulfillment services, advertising solutions, cross-border sales, payment services, and affordability solutions [3] - Hepsipay, the integrated fintech platform of Hepsiburada, offers secure payment solutions such as digital wallets, general-purpose loans, buy now pay later (BNPL), and one-click checkout, enhancing consumer shopping convenience and driving sales conversions for merchants [3] Social Impact - Since its establishment in 2000, Hepsiburada has focused on empowering women in the Turkish economy, launching the 'Technology Empowerment for Women Entrepreneurs' program in 2017, which has supported approximately 67,000 female entrepreneurs in reaching millions of customers [4]

IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (Clostridioid ...

Core Insights - BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial for its cell therapy BT-101, targeting Osteogenesis imperfecta, at the 15th International Conference on Osteogenesis imperfecta in Hong Kong [1][2] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101 as a stem cell therapy for infants with Osteogenesis imperfecta, a condition leading to fragile bones and frequent fractures [2] - Karolinska Development AB holds a 14% ownership stake in BOOST Pharma, indicating its investment in innovative medical solutions [4] Clinical Trial Results - Long-term results from the BOOSTB4 trial show that over 50% of treated patients did not experience any bone fractures in the second year after the last dose [3] - The previously reported 70% reduction in fractures during the first year was maintained and improved, leading to an overall reduction of nearly 78% compared to the pre-treatment period [3] Therapeutic Potential - The results from BOOST Pharma suggest that BT-101 has a robust therapeutic effect and potential as a disease-modifying treatment in a field with significant medical need and no adequate existing treatments [4]